Benitec Biopharma Files 8-K
Ticker: BNTC · Form: 8-K · Filed: Mar 19, 2025 · CIK: 1808898
| Field | Detail |
|---|---|
| Company | Benitec Biopharma INC. (BNTC) |
| Form Type | 8-K |
| Filed Date | Mar 19, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, financial-statements
TL;DR
Benitec Biopharma filed an 8-K for Reg FD and financials. Nothing major disclosed yet.
AI Summary
On March 19, 2025, Benitec Biopharma Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events beyond the filing itself are detailed in the provided text.
Why It Matters
This filing indicates that Benitec Biopharma Inc. is making a regulatory disclosure and providing financial statements, which is a standard requirement for public companies.
Risk Assessment
Risk Level: low — The filing is a routine regulatory disclosure and does not contain information about significant risks or material adverse events.
Key Numbers
- 001-39267 — SEC File Number (Identifies the company's filing with the SEC.)
- 84-4620206 — IRS Employer Identification No. (Tax identification number for the company.)
Key Players & Entities
- Benitec Biopharma Inc. (company) — Registrant
- March 19, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Hayward, California (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on March 19, 2025.
In which state was Benitec Biopharma Inc. incorporated?
Benitec Biopharma Inc. was incorporated in Delaware.
What is the principal executive office address for Benitec Biopharma Inc.?
The principal executive office address is 3940 Trust Way, Hayward, California, 94545.
Does this filing disclose any specific new business developments or financial results?
The provided text of the filing does not detail specific new business developments or financial results; it primarily states the nature of the filing (Regulation FD Disclosure, Financial Statements and Exhibits).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 19, 2025 regarding Benitec Biopharma Inc. (BNTC).